Effects of medical therapies for acromegaly on glucose metabolism
Authors:
- C UrbaniCUC Urbani
- C SardellaCSC Sardella
- A CalevroACA Calevro
- G RossiGRG Rossi
- I ScattinaISI Scattina
- M LombardiMLM Lombardi
- I LupiILI Lupi
- L ManettiLML Manetti
- E MartinoEME Martino
- F BogazziFBF Bogazzi
- 1 July 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 169 (1) , 99-108
Abstract
Objective: Abnormalities of glucose metabolism are common findings of acromegaly. However, robust evidence on whether therapy with somatostatin analogs (SSAs) or pegvisomant (PEG) differently affects glucose metabolism is lacking. The purpose of this study was to evaluate the effects of therapy with SSAs, PEG, or their combination on glucose metabolism in a large series of acromegalic patients.Design: This was a historical–prospective study. Among 50 consecutive acromegalic patients under SSA therapy, acromegaly in 19 patients was controlled. PEG used in combination with SSA therapy allowed the control of acromegaly in the remaining 31 patients and was then continued as monotherapy in 18 patients.Methods: The following parameters were evaluated at the diagnosis of acromegaly and during different treatments: fasting plasma glucose (FPG) and insulin concentrations, insulin sensitivity (QUICK-I), homeostasis model assessment of insulin resistance (HOMA2-IR), and plasma glucose and insulin concentrations during the oral glucose tolerance test (OGTT). Comparison was made using analysis for paired data.Results: Insulin resistance improved when acromegaly was controlled with therapy with SSAs, PEG, or SSA+PEG. However, FPG concentrations were higher during SSA therapy (alone or combined with PEG) than at the diagnosis of acromegaly, even when corrected for disease activity, whereas they were reduced during PEG therapy. Mean glucose concentrations during the OGTT were higher in patients receiving SSA therapy than in those receiving PEG therapy. In addition, the prevalence of diabetes or impaired glucose tolerance was higher during SSA therapy than at diagnosis or during PEG therapy and was not influenced by disease control.Conclusions: Medical therapies for acromegaly reduce insulin resistance and increase insulin sensitivity; on the contrary, glucose indexes may be differently affected by SSA or PEG therapy.Keywords
This publication has 36 references indexed in Scilit:
- Effects of Growth Hormone on Glucose, Lipid, and Protein Metabolism in Human SubjectsEndocrine Reviews, 2009
- AcromegalyEndocrinology and Metabolism Clinics of North America, 2008
- Mechanisms of Disease: metabolic effects of growth hormone and insulin-like growth factor 1Nature Clinical Practice Endocrinology & Metabolism, 2007
- First-line therapy of acromegaly: A statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study GroupJournal of Endocrinological Investigation, 2006
- Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and ManagementEndocrine Reviews, 2004
- A Comparison of the Effects of Pegvisomant and Octreotide on Glucose, Insulin, Gastrin, Cholecystokinin, and Pancreatic Polypeptide Responses to Oral Glucose and a Standard Mixed MealThe Journal of Clinical Endocrinology & Metabolism, 2002
- Effect of octreotide on glucose tolerance in acromegalyEuropean Journal of Endocrinology, 1994
- AN ASSESSMENT OF GLUCOSE INTOLERANCE IN ACROMEGALY AND ITS RESPONSE TO MEDICAL TREATMENTClinical Endocrinology, 1980
- INHIBITION OF INSULIN SECRETION BY SOMATOSTATINThe Lancet, 1973
- Changes of Carbohydrate Tolerance in Acromegaly with Progress of the Disease and in Response to TreatmentThe Journal of Clinical Endocrinology & Metabolism, 1967